The Cost of Uncertainty: How Analytical Chemistry Drives Billion-Dollar Decisions in Pharma
Nithya Karakala, Scientist I, Veranova
Analytical chemistry reduces uncertainty across pharmaceutical development by generating reliable data that supports critical decisions in quality, safety, manufacturing, and regulatory compliance. Advanced analytical techniques, combined with AI, automation, and sustainable practices, accelerate development, minimise risk, strengthen regulatory confidence, and enable informed decision-making throughout the product lifecycle.
Introduction:
When Uncertainty Has a Price Tag
In pharmaceutical development, uncertainty is not an abstract scientific inconvenience. It has a cost, a timeline, a regulatory consequence, and ultimately a patient impact. A promising medicine may have strong biological rationale, compelling early data, and significant commercial potential, yet still face a fundamental question: do we truly understand the product well enough to develop, manufacture, approve, and supply it with confidence?
Analytical chemistry helps answer that question. It transforms molecular complexity into measurable evidence. It tells development teams what a product is, how pure it is, how stable it remains, what impurities it contains, how it behaves under stress, whether batches are comparable, and whether a manufacturing process is under control. These are not merely technical questions. They influence whether a company advances a program, repeats a study, changes a process, delays a filing, releases a batch, responds to a regulator, or invests in commercial capacity.
Uncertainty becomes expensive when it remains invisible. Analytical chemistry does not eliminate risk, but it makes risk measurable, interpretable, and manageable. That is why it should be viewed not only as a laboratory function, but as a strategic capability across the pharmaceutical lifecycle.
The Science of Reducing Uncertainty
Every pharmaceutical product must move from scientific possibility to controlled reality. Whether the product is a small molecule, biologic, vaccine, mRNA medicine, lipid nanoparticle, gene therapy, or cell-based product, it must be characterised before it can be trusted. Analytical chemistry provides the tools and methods to build that trust.
Core analytical techniques such as chromatography, spectroscopy, mass spectrometry, electrophoresis, dissolution testing, potency assays, and stability-indicating methods help define a medicine’s quality profile. They allow scientists to identify active ingredients, quantify impurities, monitor degradation, assess potency, and determine whether the product remains within acceptable limits. For complex products, analytical chemistry becomes even more important because critical quality attributes may be interdependent, difficult to measure, or sensitive to process changes.
The value of analytical chemistry lies not only in generating data, but in generating decision-grade evidence. A test result is useful only if the method is scientifically appropriate, reproducible, validated or qualified for its intended use, and interpreted in context. Poor methods can create false confidence or unnecessary alarm. Strong methods allow organisations to distinguish true product risk from noise, variation, or artifact.
From Measurement to Business Decisions
Pharmaceutical leaders often think of major business decisions in terms of clinical data, market opportunity, competitive dynamics, or regulatory strategy. Yet analytical evidence quietly shapes many of those same decisions.
A go/no-go decision after early development depends partly on whether the candidate can be manufactured reproducibly and characterised adequately. A decision to enter late-stage clinical development depends on whether clinical trial material can be supplied consistently and whether product quality attributes are understood. A decision to scale manufacturing requires confidence that process changes will not meaningfully alter the product. A regulatory submission depends on analytical evidence demonstrating identity, strength, quality, purity, potency, stability, and control. A commercial launch depends on validated methods, release testing, stability data, specifications, and reliable supply.
When analytical uncertainty is high, leaders may delay a program, proceed while accepting additional risk, or invest in reformulation, process development, or method redevelopment. Each option carries a cost. A delayed clinical trial may lose a competitive advantage. A repeated manufacturing run may consume scarce capacity. A regulatory deficiency may extend review timelines. A failed batch may threaten supply.
In this way, analytical chemistry converts measurement into business value by reducing the unknowns that would otherwise slow or destabilise development.
The High Cost of Poor Characterisation
Poor characterisation can be one of the most expensive problems in drug development because it often emerges late, after substantial investment has already been made. Early-stage programs may move quickly with limited analytical understanding, but unresolved questions can compound over time.
An unidentified impurity may later require toxicological assessment, regulatory justification, or process redesign. An unstable formulation may force additional development work or limit shelf life. A potency assay with high variability may make it difficult to interpret product consistency. A method that works in research may fail when transferred to quality control. A degradation pathway that was not recognised early may become a major concern during stability studies.
The direct costs include additional experiments, delayed submissions, repeated validation work, batch rejection, deviation investigations, and extended regulatory interactions. The indirect costs may be even greater: missed market windows, pressure on clinical supply, reputational damage, and opportunity costs as resources are diverted from other programs.
Poor characterisation is not simply a technical gap. It is a business risk. Strong analytical strategies identify product liabilities early, when they are less expensive to address, and help companies avoid advancing candidates that are biologically promising but operationally fragile.
Analytical Chemistry Across the Lifecycle
Analytical chemistry creates value at every stage of pharmaceutical development. In discovery and candidate selection, it confirms identity, purity, stability, and developability. A compound or platform may show promising biological activity, but if it is unstable, difficult to characterise, or prone to problematic impurities, its long-term value may be limited. Early analytical insight helps teams avoid costly commitment to weak candidates.
In preclinical and IND-enabling development, analytical chemistry supports toxicology studies, formulation selection, impurity control, and initial stability assessment. The material used in nonclinical studies must be understood because those studies form part of the safety foundation for human exposure. Analytical methods also begin to define the emerging control strategy.
During clinical development, analytical chemistry supports continuity. Clinical trial material must be manufactured, released, stored, shipped, and administered under conditions that preserve quality. If the process, formulation, site, scale, or raw materials change, analytical comparability becomes essential. Without reliable comparability data, clinical interpretation and regulatory confidence may be weakened.
In commercial manufacturing, analytical chemistry becomes central to quality assurance. Batch release, in-process controls, stability programs, reference standards, method validation, process validation, and continued process verification all depend on analytical methods. The question is whether the product can be made consistently, at scale, across time, sites, and markets.
After approval, analytical chemistry supports lifecycle management. Shelf-life extension, site transfers, process improvements, new presentations, global submissions, and post-approval commitments all require analytical evidence. In this sense, analytical chemistry protects not only development investment but also long-term product value.
Digital Analytical Chemistry and Predictive Quality
The role of analytical chemistry is expanding as laboratories become more digital, automated, and data-rich. Traditional testing remains essential, but it is increasingly supported by artificial intelligence, machine learning, robotics, advanced data analytics, process analytical technology, and real-time monitoring.
This shift moves analytical chemistry from retrospective testing toward predictive quality. Instead of asking only whether a batch met specifications, companies can ask whether a process is drifting, whether an impurity trend is emerging, whether a stability risk can be predicted, or whether manufacturing conditions can be adjusted before failure occurs.
Machine vision can detect defects, monitor coating uniformity, inspect packaging, and support automated quality control. Predictive analytics can identify equipment risks and reduce unplanned downtime. Advanced laboratory systems can analyse complex datasets faster and more consistently than manual review alone.
However, digital tools do not replace analytical science. They depend on it. Artificial intelligence is only as reliable as the data, assumptions, methods, and controls behind it. Poor data quality or limited understanding of the method can turn digital acceleration into digital uncertainty. The future will require scientists who can integrate chemistry, statistics, data science, automation, regulatory expectations, and quality systems.
White Analytical Chemistry: Performance, Sustainability, and Practicality
Modern analytical excellence must balance more than sensitivity and accuracy. A method may be scientifically impressive but still fail to create value if it is too slow, too expensive, too solvent-intensive, difficult to transfer, or unsuitable for routine quality control. This is why White Analytical Chemistry provides a useful framework for the future.
White Analytical Chemistry emphasises three dimensions: analytical performance, environmental sustainability, and practical feasibility. In pharmaceutical terms, methods should be reliable, scalable, transferable, cost-conscious, safer, and aligned with quality and regulatory expectations.
This broader view matters because analytical methods live beyond the research laboratory. They may need to support global quality control networks, regulatory filings, stability programs, commercial release, and lifecycle changes. A strong method must work not only under ideal conditions but also in real operational environments.
Sustainable method development also has business value. Reducing solvent use, hazardous waste, energy consumption, and complex sample preparation can lower operating costs, improve laboratory safety, and support corporate sustainability goals. When performance, practicality, and sustainability are integrated, analytical chemistry becomes more efficient and more strategically useful.
Regulatory Confidence and the Value of Evidence
Regulatory agencies expect sponsors to understand and control their products. Analytical chemistry provides much of the evidence needed to demonstrate that understanding. A strong submission tells a coherent story: the product is well characterised, critical quality attributes are understood, impurities and degradation pathways are controlled, methods are suitable, specifications are justified, and stability data support the proposed shelf life.
When analytical evidence is strong, regulatory interactions become more constructive.
Questions can be answered clearly. Comparability arguments become more persuasive. Control strategies are easier to defend. Post-approval flexibility may be greater because the product and process are better understood.
When analytical evidence is weak, uncertainty shifts to the regulator. Agencies may request additional data, question specifications, challenge method suitability, or delay approval. Regulatory confidence is not built at the end of development; it is built through years of analytical decisions.
Conclusion: What Pharma Cannot Measure Can Cost It
Pharmaceutical development will always involve uncertainty. Biology is complex, manufacturing is demanding, patients are diverse, and regulatory expectations are high. The goal is not to remove uncertainty entirely. The goal is to recognise it early, measure it accurately, interpret it wisely, and manage it before it becomes expensive.
Analytical chemistry is central to that goal. It defines what a product is, how it behaves, how it changes, and how it can be controlled. It supports decisions across discovery, development, manufacturing, regulatory review, commercialisation, and lifecycle management. It protects patients by ensuring quality, and it protects companies by reducing avoidable scientific, operational, and regulatory risk.
In a business where a single delay, failed batch, or regulatory setback can carry enormous consequences, analytical chemistry is not a back-office laboratory service. It is decision infrastructure: the way pharma converts uncertainty into evidence, and evidence into action.
What pharma cannot measure, it cannot fully understand. And what it cannot understand can become far more expensive than expected.
Nithya Karakala is an accomplished pharmaceutical scientist with more than 12 years of experience in analytical chemistry and inhalation drug development. She holds an MBA from Boston University, a PGPM from the University of Massachusetts, and an MSc in Pharmaceutical Analysis from the University of Strathclyde. Her career spans roles at leading pharmaceutical companies, including Novartis, GSK, and Pfizer. She is currently part of the team at Veranova.
